A new treatment option for people with kidney cancer

The National Institute for Health and Care Excellence (NICE) recommends cabozantinib as an option for people with advanced renal cell carcinoma (RCC). The NICE appraisal committee were unable to recommend cabozantinib following their initial assessment of the drug in February 2017. This was because they felt some of the clinical evidence presented by the company was unreliable. In response to this, the company revised their submission to strengthen the evidence. The NICE committee have since concluded cabozantinib is a cost-effective, viable treatment option for people who have advanced RCC. RCC starts in cells lining the small tubes in the kidney that help